SGLT-2 inhibitors tied to lower risk for autoimmune rheumatic diseases in adults with type 2 diabetes

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes, according to a study published online Oct. 15 in The BMJ.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup